Biogen Inc. reported adjusted earnings per share of $5.47 for the second quarter of 2025, up 4% year over year, surpassing analyst consensus of $4.06. Sales were $2.65 billion, up 7% year over year, beating expectations of $2.32 billion. Multiple sclerosis revenue decreased by 4% to $1.1 billion, with Tysabri sales down to $454.6 million. Rare disease revenue increased by 2% to $543 million, with Spinraza revenue down to $392.7 million. Skyclarys revenue reached $130.3 million, showing growth. In Alzheimer’s disease, Leqembi’s U.S. sales grew by 20%. Global in-market sales were approximately $160 million. Biogen raised its 2025 adjusted earnings guidance to $15.50-$16.00 per share. Total revenue for 2025 is expected to be flat compared to 2024, reflecting strong performance in the first half. The company expects increased competitive pressures in the second half, particularly in Europe. Minimal contract manufacturing revenue is expected in the fourth quarter of 2025 due to planned maintenance activities. Potential tariffs are not expected to affect the financial outlook for 2025. The Fit for Growth program is expected to generate $1 billion of gross savings and $800 million net of reinvestment by the end of 2025. Biogen plans to make additional investments in R&D to support rare diseases, with combined expenses totaling approximately $4 billion in 2025. BIIB stock is trading higher by 3.01% at $130.45.

Read more at Yahoo Finance: Biogen Lifts Outlook As Rare Disease And Alzheimer’s Drug Sales Accelerate